US patent granted for Tumorad®
Spago Nanomedical AB (publ) announce today that the United States Patent and Trademark Office (USPTO) has granted the company´s patent application comprising product protection for Tumorad® in the USA.Tumorad® is based on nanoparticles loaded with a radioisotope and holds potential to become a new treatment of solid tumors. Earlier this year the USPTO issued a preliminary approval by means of a Notice of Allowance. The USPTO has now informed Spago Nanomedical that the patent was approved on June 19. The patent, with the title “Nanostructures and applications thereof”, has been assigned